Erythromycin targets bacterial ribosomes — the nanomachine responsible for the translation of messenger RNA (mRNA) sequences into protein — thus preventing synthesis of the proteins required for continued growth and survival.
To build new varieties of erythromycin with a slightly different shape, scientists can theoretically target any part of this assembly line, using various techniques to affix parts with structures that deviate slightly from the originals.